Tag: CRSP

  • How to Trade the Gene Editing Excitement

    How to Trade the Gene Editing Excitement

    By now, you’ve heard about gene editing. Or, the ability to alter, remove, and even add a DNA sequence to help treat countless disorders we never thought treatable. At the moment, there are about 7,000 diseases caused by genetic disorders, which occur when a mutation affects your genes, or when you have the wrong amount…

  • Halted: CRISPR Could Explode on US FDA Decision

    Halted: CRISPR Could Explode on US FDA Decision

    Keep an eye on CRISPR Therapeutics (CRSP). At the moment, it’s halted. But it could get explosive if the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee green lights the company’s Biologics License Application (BLA) for exagamglogene autotemcel (exa-cel) for the treatment of sickle cell disease (SCD) in people ages…

  • Why CRISPR is Becoming a Standout Winner

    Why CRISPR is Becoming a Standout Winner

    CRISPR Therapeutics could be a standout winner this year, we said on April 13. We also noted, “Cantor Fitzgerald initiated coverage with an outperform rating, with a $72 price target, with the firm expecting CRSP to get a nod for its gene-editing therapy, exa-cel.” At the time, CRSP traded around $44.  Today, it’s up to…

  • Top Ways to Trade the Gene Editing Boom

    Top Ways to Trade the Gene Editing Boom

    By now, you’ve heard about gene editing. Or, the ability to alter, remove, and even add a DNA sequence to help treat countless disorders we never thought treatable. Right now, there are about 7,000 diseases caused by genetic disorders, which occur when a mutation affects your genes, or when you have the wrong amount of…

  • CRISPR Therapeutics Could be a Standout Winner this Year

    CRISPR Therapeutics Could be a Standout Winner this Year

    Gene editing stocks, like CRISPR Therapeutics (CRSP), are on the. move. In fact, CRSP is up about 15% on the day on a volume spike to 2.6 million shares, as compared to daily average volume of 1.04 million.  All after analysts at Cantor Fitzgerald initiated coverage with an outperform rating, with a $72 price target. …